The Court of Appeals (CA) has denied Sanofi Pasteur’s motion for reconsideration regarding its Dengvaxia dengue vaccine, upholding a previous decision that revoked the vaccine’s certificates of product registration (CPRs) in 2018.
The revocation followed Sanofi’s 2017 disclosure that Dengvaxia posed risks to individuals who had not previously contracted the virus, leading the Philippine government to halt its national vaccination program.
In a resolution dated September 20, the CA dismissed Sanofi’s petition for review, reaffirming the permanent revocation of the CPRs.
Associate Justice Eduardo Ramos Jr. noted that the arguments presented in the motion had already been deemed without merit.
As a result, the ban on Dengvaxia remains in effect.
Source: PhilNews24 | September 26, 2024
SANOFI’S DENGVAXIA APPEAL DISMISSED BY COURT OF APPEALS
Latest from News
Former DPWH chief Babes Singson and SGV managing partner Rossana Fajardo were appointed commissioners of President
The Zambales provincial government has terminated two major infrastructure projects worth nearly P1 billion after the
The Department of Labor and Employment (DOLE) will roll out P559 million in aid and open
The Armed Forces of the Philippines (AFP) participated in the 3rd Quarter 2025 National Simultaneous Earthquake
US Secretary of State Marco Rubio expressed support for the Philippines in opposing China’s plan to